MBG453
CMBG453E12101
Phase 1 small_molecule terminated
Quick answer
MBG453 for Myelodysplastic Syndromes is a Phase 1 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Myelodysplastic Syndromes
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated